spacer
home > > autumn 2003 > how clinical trials supplies labelling may be affected by the extended eu local language requirements and how integrated labelling systems could provide a solution
PUBLICATIONS


How Clinical Trials Supplies Labelling May Be Affected by the Extended EU Local Language Requirements and How Integrated Labelling Systems Could Provide a Solution

This article is intended to keep readers informed about the developments concerning the local language requirements for EU member states when producing clinical trials supplies labels. The first part of the article deals with the reasons why the EU's local language requirement is about to become more difficult to meet, and the second part offers some potential solutions.

EU Expansion

Many labelling requirements are listed within the current regulatory framework and are transposed across all member states in Europe. Member states require labelling in their national language when the clinical trials supply product reaches the patient. Member states may authorise information to be in one or more community languages. The local language requirements are not new in themselves; it's just the ever-increasing number of languages required on the label and our customers' experiences of increased inspection activities in this area.

It is now almost certain that Eastern European countries will enact similar legislation regarding the need for local language labelling due to the planned expansion of the EU scheduled for 1 st May 2004 - under one year from now. The existing list of 15 members will be expanded to include 10 more from May 2004. The new countries are: Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovak Republic and Slovenia. These countries are currently known as the 'acceding countries' and are all on schedule to meet the joining requirements. It is also expected that Bulgaria and Romania will join the EU in 2007. Part of the requirement for expanded membership is for each country to adopt the common rules, standards and policies that make up the body of the EU law. Once again, it is almost certain that the new EU countries will adopt the local language requirements. This will result in clinical trials supplies labels needing to handle the wider language requirements, which some systems struggle to cope with at the moment.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Bob Tilling, Director of New Business Development at MAP80 Systems Limited

Bob Tilling is the Director of New Business Development for MAP80 Systems Limited, a UK-based developer of labelling software for the pharmaceutical and medical industries. Bob has over eight years' experience with major labelling projects for well-known pharmaceutical, medical and clinical trials companies. His advice has assisted many companies in solving such labelling problems as the local language requirement for products distributed worldwide and the use of labelling software within a GMP environment. Recently, Bob has been providing advice to companies considering the implementation of a single worldwide labelling system and has presented papers on this subject at several industry seminars.

spacer
Bob Tilling
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Business Continuity Plan - Message from Protagen Protein Services (PPS)

Following the recent COVID-19 outbreak, we at Protagen Protein Services (PPS) are preparing for all eventualities. Please be assured that PPS will continue to operate as normal providing you with all of the professional support and service you have to come to expect from us. Given the gravity of the situation, and to protect our staff, clients, and communities from the spread of the virus, we have taken various measures within a scope of a Business Continuity Plan:
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein´┐Żs primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement